Page 3 - Five Prime News Today

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that ...

Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Amgen Inc (NASDAQ: AMGN) Operator My name is Erica, and I will be your conference facilitator today for Amgens First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.SPONSORED: 10 stocks we like better than Amgen...

Amgen today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b overexpressing and human epidermal growth factor receptor 2 -negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 based on … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration ...

Breakthrough designation granted for Amgen’s bemarituzumab 20th April 2021 Amgen’s investigational medicine bemarituzumab has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA). The FDA has granted bemarituzumab a BTD for the first-line treatment of patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (G...

socaltech.com Thousand Oaks-based Amgen said this morning that it has successfully completed its $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics. Five Primes programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.

Press release content from PR Newswire. The AP news staff was not involved in its creation. Amgen Successfully Completes Acquisition Of Five Prime Therapeutics April 16, 2021 GMT Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/) THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage bi...

Aulos Bioscience Appoints Aron Knickerbocker as CEO News provided by Share this article Share this article BOSTON and TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Aron Knickerbocker has joined the company as its chief executive officer and a member of its board of directors, effective immediately. Yan...

PharmiWeb.com is Europes leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2021.4.7.1 You are leaving PharmiWeb.com Disclaimer...

Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m. EST THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 – Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, represen...

Moore Kuehn Encourages FPRX, SVBI, SOAC, and CAP Investors to Contact Law Firm News provided by Share this article Share this article NEW YORK, March 5, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of...